Gilead Sciences (GILD) has attracted fresh attention after the FDA approved Trodelvy for first-line treatment of advanced triple-negative breast cancer, with the therapy also added as a preferred option in NCCN Guidelines.

The Trodelvy approval has coincided with a sharp pickup in interest around Gilead Sciences, with the share price now at $136.36 and a 7.93% 7-day share price return. The 1-year total shareholder return of 25.98% and 5-year total shareholder return of 140.64% point to momentum that has generally been building over time, despite a 3-month share price return that declined 3.66% and recent removals from several Russell growth indices.

If Trodelvy and cell therapy progress has your attention, it could be a good moment to broaden your healthcare watchlist using our screener for 40 healthcare AI stocks

After the Trodelvy news and a strong 1-year run for Gilead Sciences, the question becomes simple: pay up at today’s price or wait for a cleaner entry, and how does the current valuation frame that choice?

Most Popular Gilead Sciences Narrative: 6.2% Overvalued

According to the most followed narrative on Gilead Sciences, the fair value sits at $128.38 compared with the recent $136.36 close, which puts the current price slightly ahead of that view.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers in lenacapavir and Trodelvy, and high-upside optionality in cell therapy and immunology. Temporary earnings headwinds from acquisitions and pipeline build-out are seen as an investment phase rather than a structural issue, with the valuation anchored on stronger cash generation as these platforms mature.

Curious what sits behind that $128.38 fair value for Gilead Sciences? The narrative leans heavily on earnings growth, margin resilience, and a future profit multiple that assumes real staying power. Want to see which financial levers matter most in that equation.

Result: Fair Value of $128.38 (OVERVALUED)

However, two pressure points could unsettle that Gilead Sciences fair value: weaker than expected Trodelvy uptake in new settings and any setback across the cell therapy portfolio.

Another View on Gilead Sciences: Cash Flows Tell a Different Story

While the most followed narrative has Gilead Sciences as 6.2% overvalued at $136.36 versus a $128.38 fair value, the SWS DCF model points in the opposite direction. On that framework, Gilead trades at a 53.4% discount to an estimated fair value of $292.65, which is a wide gap for any large biopharma. Which lens do you trust more when the cash flow model and narrative-based fair value disagree this much?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Gilead Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Conflicted by the mix of optimism and concern around Gilead Sciences? Take a closer look at the full picture and weigh both sides through the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Gilead Sciences?

If Gilead Sciences has sharpened your focus, do not stop here. Broaden your opportunity set now with targeted stock ideas built from clear, transparent data.

• Spot potential bargains on your terms by scanning 45 high quality undervalued stocks that combine quality fundamentals with prices that may sit below their implied worth.
• Prioritise staying power by reviewing solid balance sheet and fundamentals stocks screener (47 results) built around companies with financial profiles that can better handle tougher conditions.
• Get ahead of the crowd by checking screener containing 18 high quality undiscovered gems before wider attention arrives and pushes these stocks into the spotlight.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.